Chava Kimchi-Sarfaty

List of Publications by Year
in descending order

88	7,457	172457 29	62596 80
papers	citations	h-index	g-index

123	123	123	10563
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	An Optimized Purification Design for Extracting Active ADAMTS13 from Conditioned Media. Processes, 2022, 10, 322.	2.8	0
2	Structural, functional, and immunogenicity implications of F9 gene recoding. Blood Advances, 2022, 6, 3932-3944.	5.2	4
3	Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes. Journal of the National Cancer Institute, 2022, 114, 1072-1094.	6.3	9
4	Gene variants of coagulation related proteins that interact with SARS-CoV-2. PLoS Computational Biology, 2021, 17, e1008805.	3.2	18
5	In Silico Evaluation of Cyclophilin Inhibitors as Potential Treatment for SARS-CoV-2. Open Forum Infectious Diseases, 2021, 8, ofab189.	0.9	5
6	Distinct signatures of codon and codon pair usage in 32 primary tumor types in the novel database CancerCoCoPUTs for cancer-specific codon usage. Genome Medicine, 2021, 13, 122.	8.2	4
7	New approaches to predict the effect of co-occurring variants on protein characteristics. American Journal of Human Genetics, 2021, 108, 1502-1511.	6.2	3
8	Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design. Scientific Reports, 2020, 10, 15643.	3.3	46
9	Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus. Thrombosis and Haemostasis, 2020, 120, 1668-1679.	3.4	75
10	In silico features of ADAMTS13 contributing to plasmatic ADAMTS13 levels in neonates with congenital heart disease. Thrombosis Research, 2020, 193, 66-76.	1.7	2
11	Polyethylene Oxide Molecular Size Determines the Severity of Atypical Thrombotic Microangiopathy in a Guinea Pig Model of Acute Intravenous Exposure. Toxicological Sciences, 2020, 177, 235-247.	3.1	3
12	TissueCoCoPUTs: Novel Human Tissue-Specific Codon and Codon-Pair Usage TablesÂBased on Differential Tissue Gene Expression. Journal of Molecular Biology, 2020, 432, 3369-3378.	4.2	28
13	Ribosome profiling of HEK293T cells overexpressing codon optimized coagulation factor IX. F1000Research, 2020, 9, 174.	1.6	2
14	Ribosome profiling of HEK293T cells overexpressing codon optimized coagulation factor IX. F1000Research, 2020, 9, 174.	1.6	3
15	Splicing dysregulation contributes to the pathogenicity of several F9 exonic point variants. Molecular Genetics & Genomic Medicine, 2019, 7, e840.	1.2	13
16	Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies. Scientific Reports, 2019, 9, 15449.	3.3	38
17	Codon and Codon-Pair Usage Tables (CoCoPUTs): Facilitating Genetic Variation Analyses and Recombinant Gene Design. Journal of Molecular Biology, 2019, 431, 2434-2441.	4.2	100
18	The Kazusa codon usage database, CoCoPUTs, and the value of up-to-date codon usage statistics. Infection, Genetics and Evolution, 2019, 73, 266-268.	2.3	8

#	Article	IF	Citations
19	Translational and transcriptional responses in human primary hepatocytes under hypoxia. American Journal of Physiology - Renal Physiology, 2019, 316, G720-G734.	3.4	7
20	A Single Synonymous Variant (c.354G>A [p.P118P]) in ADAMTS13 Confers Enhanced Specific Activity. International Journal of Molecular Sciences, 2019, 20, 5734.	4.1	23
21	von Willebrand factor/ADAMTSâ€13 interactions at birth: implications for thrombosis in the neonatal period. Journal of Thrombosis and Haemostasis, 2019, 17, 429-440.	3.8	18
22	Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B. Journal of Medical Genetics, 2017, 54, 338-345.	3.2	66
23	The importance of <scp>mRNA</scp> structure in determining the pathogenicity of synonymous and nonâ€synonymous mutations in haemophilia. Haemophilia, 2017, 23, e8-e17.	2.1	31
24	A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER. Blood, 2017, 129, 896-905.	1.4	30
25	Compounding variants rescue the effect of a deleterious ADAMTS13 mutation in a child with severe congenital heart disease. Thrombosis Research, 2017, 158, 98-101.	1.7	4
26	Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels. Blood Advances, 2017, 1, 1037-1046.	5.2	20
27	Recent advances in (therapeutic protein) drug development. F1000Research, 2017, 6, 113.	1.6	348
28	A new and updated resource for codon usage tables. BMC Bioinformatics, 2017, 18, 391.	2.6	182
29	Elevated preoperative von Willebrand factor is associated with perioperative thrombosis in infants and neonates with congenital heart disease. Journal of Thrombosis and Haemostasis, 2017, 15, 2306-2316.	3.8	14
30	Genetic Polymorphisms of P-glycoprotein: Echoes of Silence. , 2016, , 105-134.		3
31	Selectable Markers for Gene Therapy. , 2015, , 701-740.		0
32	Genetic determinants of immunogenicity to factorIXduring the treatment of haemophilia B. Haemophilia, 2015, 21, 210-218.	2.1	18
33	Small ncRNA Expression-Profiling of Blood from Hemophilia A Patients Identifies miR-1246 as a Potential Regulator of Factor 8 Gene. PLoS ONE, 2015, 10, e0132433.	2.5	22
34	Personalized approaches to the treatment of hemophilia A and B. Personalized Medicine, 2015, 12, 403-415.	1.5	2
35	Factor <scp>IX</scp> oligomerization underlies reduced activity upon disruption of physiological conditions. Haemophilia, 2014, 20, e157-63.	2.1	1
36	Single-nucleotide variations defining previously unreportedADAMTS13haplotypes are associated with differential expression and activity of the VWF-cleaving protease in a Salvadoran congenital thrombotic thrombocytopenic purpura family. British Journal of Haematology, 2014, 165, 154-158.	2.5	5

#	Article	IF	Citations
37	Exposing synonymous mutations. Trends in Genetics, 2014, 30, 308-321.	6.7	272
38	MDR1 Synonymous Polymorphisms Alter Transporter Specificity and Protein Stability in a Stable Epithelial Monolayer. Cancer Research, 2014, 74, 598-608.	0.9	103
39	A Gene-Specific Method for Predicting Hemophilia-Causing Point Mutations. Journal of Molecular Biology, 2013, 425, 4023-4033.	4.2	30
40	Higher-Order Structure and Protein Aggregate Characterization of Protein Therapeutics: Perspectives from Good Manufacturing Practices and Regulatory Guidance. , 2013, , 261-281.		1
41	Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13481-13486.	7.1	147
42	Endogenous factor VIII synthesis from the intron 22â€“inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nature Medicine, 2013, 19, 1318-1324.	30.7	59
43	Building better drugs: developing and regulating engineered therapeutic proteins. Trends in Pharmacological Sciences, 2013, 34, 534-548.	8.7	77
44	Multiple in silico tools predict phenotypic manifestations in congenital thrombotic thrombocytopenic purpura. British Journal of Haematology, 2013, 160, 825-837.	2.5	14
45	Sensitive measurement of single-nucleotide polymorphism-induced changes of RNA conformation: application to disease studies. Nucleic Acids Research, 2013, 41, 44-53.	14.5	86
46	ADAMTS13: The von Willebrand Factor Cleaving Protease and Its Role in Thrombotic Thrombocytopenic Purpura. , 2013, , 257-276.		0
47	Cyclosporin A Impairs the Secretion and Activity of ADAMTS13 (A Disintegrin and Metalloprotease with) Tj ETQq1 1 0.784314 rgBT /Ov	3.4	12
48	SV40 In Vitro Packaging: A Pseudovirion Gene Delivery System. Cold Spring Harbor Protocols, 2012, 2012, pdb.prot071043-pdb.prot071043.	0.3	1
49	Plasma derivatives: New products and new approaches. Biologicals, 2012, 40, 191-195.	1.4	8
50	Analysis of F9 point mutations and their correlation to severity of haemophilia B disease. Haemophilia, 2012, 18, 933-940.	2.1	12
51	Detecting SNP-Induced Structural Changes in RNA: Application to Disease Studies. Lecture Notes in Computer Science, 2012, , 241-243.	1.3	5
52	Characterization of Coding Synonymous and Non-Synonymous Variants in ADAMTS13 Using Ex Vivo and In Silico Approaches. PLoS ONE, 2012, 7, e38864.	2.5	61
53	Secretion and Activity of ADAMTS13 Are Impaired by Cyclosporin A. Blood, 2012, 120, 3349-3349.	1.4	0
54	Detection of a secreted metalloprotease within the nuclei of liver cells. Molecular BioSystems, 2011, 7, 2012.	2.9	7

#	Article	IF	Citations
55	Inhibition of Multidrug Resistance by SV40 Pseudovirion Delivery of an Antigene Peptide Nucleic Acid (PNA) in Cultured Cells. PLoS ONE, 2011, 6, e17981.	2.5	18
56	Understanding the contribution of synonymous mutations to human disease. Nature Reviews Genetics, 2011, 12, 683-691.	16.3	815
57	SNPs in ADAMTS13. Pharmacogenomics, 2011, 12, 1147-1160.	1.3	8
58	Pseudovirions as Vehicles for the Delivery of siRNA. Pharmaceutical Research, 2010, 27, 400-420.	3.5	17
59	A splice variant of ADAMTS13 is expressed in human hepatic stellate cells and cancerous tissues. Thrombosis and Haemostasis, 2010, 104, 531-533.	3.4	14
60	The Synonymous V107V Mutation In Factor IX Is Not So Silent and May Cause Hemophilia B In Patients. Blood, 2010, 116, 2197-2197.	1.4	5
61	Detection of intracellular ADAMTS13, a secreted zincâ€metalloprotease, via flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2009, 75A, 675-681.	1.5	3
62	Silent (Synonymous) SNPs: Should We Care About Them?. Methods in Molecular Biology, 2009, 578, 23-39.	0.9	214
63	The Development of Gene Therapy: From Monogenic Recessive Disorders to Complex Diseases Such as Cancer. Methods in Molecular Biology, 2009, 542, 5-54.	0.9	31
64	Characterization of Conformation-Sensitive Antibodies to ADAMTS13, the von Willebrand Cleavage Protease. PLoS ONE, 2009, 4, e6506.	2.5	12
65	Synonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct Minima. Journal of Molecular Biology, 2008, 383, 281-291.	4.2	230
66	Modulation of Na⁺-Ca²⁺Exchanger Expression by Immunosuppressive Drugs Is Isoform-Specific. Molecular Pharmacology, 2008, 73, 1254-1263.	2.3	8
67	Selectable Markers for Gene Therapy. , 2008, , .		0
68	Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics, 2007, 8, 29-39.	1.3	91
69	The sounds of silence: synonymous mutations affect function. Pharmacogenomics, 2007, 8, 527-532.	1.3	47
70	Silent Polymorphisms Speak: How They Affect Pharmacogenomics and the Treatment of Cancer. Cancer Research, 2007, 67, 9609-9612.	0.9	219
71	A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity. Science, 2007, 315, 525-528.	12.6	2,230
72	Cyclosporin A-Dependent Downregulation of the Na+/Ca2+ Exchanger Expression. Annals of the New York Academy of Sciences, 2007, 1099, 204-214.	3.8	9

#	Article	IF	Citations
73	SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice. Cancer Gene Therapy, 2006, 13, 648-657.	4.6	21
74	Efficient Delivery of RNA Interference Effectors via in vitro-Packaged SV40 Pseudovirions. Human Gene Therapy, 2005, 16, 1110-1115.	2.7	35
75	Efficient Delivery of RNA Interference Effectors via In Vitro-Packaged SV40 Pseudovirions. Human Gene Therapy, 2005, .	2.7	0
76	Transduction of multiple cell types using improved conditions for gene delivery and expression of SV40 pseudovirions packaged in vitro. BioTechniques, 2004, 37, 270-275.	1.8	18
77	SV40 Pseudovirions as Highly Efficient Vectors for Gene Transfer and their Potential Application in Cancer Therapy. Current Pharmaceutical Biotechnology, 2004, 5, 451-458.	1.6	33
78	P-glycoprotein: from genomics to mechanism. Oncogene, 2003, 22, 7468-7485.	5.9	956
79	High Cloning Capacity of In Vitro Packaged SV40 Vectors with No SV40 Virus Sequences. Human Gene Therapy, 2003, 14, 167-177.	2.7	43
80	Gene Expression and Detection. , 2003, , 413-480.		0
81	Transport Activity and Surface Expression of the Na+-Ca2+ Exchanger NCX1 Are Inhibited by the Immunosuppressive Agent Cyclosporin A and by the Nonimmunosuppressive Agent PSC833. Journal of Biological Chemistry, 2002, 277, 2505-2510.	3.4	14
82	Functional Characterization of Coding Polymorphisms in the HumanMDR1 Gene Using a Vaccinia Virus Expression System. Molecular Pharmacology, 2002, 62, 1-6.	2.3	154
83	In Vitro-Packaged SV40 Pseudovirions as Highly Efficient Vectors for Gene Transfer. Human Gene Therapy, 2002, 13, 299-310.	2.7	38
84	NCX1 Surface Expression. Annals of the New York Academy of Sciences, 2002, 976, 176-186.	3.8	2
85	NCX1 surface expression: a tool to identify structural elements of functional importance. Annals of the New York Academy of Sciences, 2002, 976, 176-86.	3.8	2
86	Differences in rhodamine-123 efflux in B-type chronic lymphocytic leukemia suggest possible gender and stage variations in drug-resistance gene activity. Annals of Hematology, 1998, 76, 189-194.	1.8	19
87	Efficient Transduction of Human Hematopoietic Cells with the Human Multidrug Resistance Gene 1 via SV40 Pseudovirions. Human Gene Therapy, 1998, 9, 649-657.	2.7	39
88	Paracentric inversion X(q21.2q24) associated with mental retardation in males and normal ovarian function in females. American Journal of Medical Genetics Part A, 1995, 55, 359-362.	2.4	16